Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-06-18
2011-10-04
Kosack, Joseph (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S217000
Reexamination Certificate
active
08030337
ABSTRACT:
The present invention provides a compound represented by the formulawhich is useful as an agent for the prophylaxis or treatment of diseases related to the action of melatonin, or a salt thereof and the like.
REFERENCES:
patent: 5596019 (1997-01-01), Mattson et al.
patent: 5654325 (1997-08-01), Flaugh
patent: 5753709 (1998-05-01), Keavy et al.
patent: 5889031 (1999-03-01), Keavy et al.
patent: 6034239 (2000-03-01), Ohkawa et al.
patent: 6180657 (2001-01-01), Flaugh
patent: 6262095 (2001-07-01), Boutherin-Falson et al.
patent: 6569894 (2003-05-01), Takaki et al.
patent: 2003/0216456 (2003-11-01), Takaki et al.
patent: 2006/0223877 (2006-10-01), Zemlan
patent: 1 214 944 (2002-06-01), None
patent: 1 334 732 (2003-08-01), None
patent: 2002-212063 (2002-07-01), None
patent: 94040886 (1996-09-01), None
patent: 94041028 (1996-09-01), None
patent: 96111003 (1998-09-01), None
patent: 2146140 (2000-03-01), None
patent: 2178791 (2000-06-01), None
patent: 2160101 (2000-12-01), None
patent: 2162076 (2001-01-01), None
patent: 98113147 (2006-06-01), None
patent: 2007140242 (2007-10-01), None
Guigen et al. Angew. Chem. Int. Ed. Engl. 1996, 35, 451-454.
Jarrow et al. Org. Synth, Coll. vol. 10, p. 29 (2004); vol. 76, p. 46 (1999).
Turek et al. Sleep Medicine 2004, 5, 523-532.
Dörwald, F. Zaragoza. Side Reactions in Organic Synthesis: A Guide to Successful Synthesis Design, Weinheim: WILEY-VCH Verlag GmbH & Co. KGaA, 2005, Preface.
Rautio et al. Nature Reviews Drug Discovery 2008, 7, pp. 255-270.
Wang et al. Drug Delivery: Principles and Applications, 2005 John Wiley & Sons, Inc. Publication, Section 8.3, pp. 136-137.
Smith, D. A. Current Opinion in Drug Discovery & Development 2007, 10, 550-559.
Testa, B. Current Opinion in Chemical Biology 2009, 13, pp. 338-344.
Berge et al. J. Pharm. Sci. 1997, 66, pp. 1-19.
Uchikawa et al. J. Med. Chem. 2002, 52, 4222-4239.
Li-Qiang Sun et al., “Design and synthesis of benzoxazole derivatives as novel melatoninergic ligands”, Bioorganic and Medicinal Chemistry Letters 14, 2004, pp. 1197-1200.
Li-Quang Sun et al., “Synthesis and structure-activity relationship of novel benzoxazole derivatives as melatonin receptor agonists”, Bioorganic & Medicinal Chemistry Letters 14, 2004, pp. 3799-3802.
Georgian Search Report corresponding to Georgian Patent Application No. AP 2007 011069 dated May 21, 2010.
Mashkovsky, M.D. “Medicaments”, Moscow, “Meditsina”, 2001, part 1, pp. 6-7.
Russian Office Action issued in Russian Patent Application No. 2009101299 dated Jan. 18, 2011.
Hoashi Yasutaka
Koike Tatsuki
Takai Takafumi
Uchikawa Osamu
Coughlin Matthew P
Kosack Joseph
Sughrue & Mion, PLLC
Takeda Pharmaceutical Company Limited
LandOfFree
Tricyclic compound and pharmaceutical use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tricyclic compound and pharmaceutical use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tricyclic compound and pharmaceutical use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4258661